Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Xeris Pharmaceuticals (XERS)
NASDAQ:XERS
RESEARCH TOOLSreports
Holding XERS?
Track your performance easily
XERS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.46 - $3.26
Previous Close$2.36
Volume1.89M
Average Volume (3M)1.35M
Market Cap
$349.14M
Enterprise Value$511.11M
Total Cash (Recent Filing)$65.97M
Total Debt (Recent Filing)$227.94M
Price to Earnings (P/E)―
Beta1.71
Next Earnings
Aug 07, 2024EPS Estimate
-$0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.46
Shares Outstanding148,255,663
10 Day Avg. Volume1,161,667
30 Day Avg. Volume1,348,549
Standard Deviation0.25
R-Squared0.15
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)70.33
Price to Sales (P/S)8.23
Price to Cash Flow (P/CF)-5.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.46
Enterprise Value/Gross Profit16.78
Enterprise Value/Ebitda-34.09
Forecast
1Y Price Target
$4.75Price Target Upside91.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Xeris Pharmaceuticals News
PremiumCompany Announcements
Xeris Pharmaceuticals Appoints Kevin McCulloch as President and COO
PremiumCompany Announcements
Xeris Pharmaceuticals Undergoes Executive Leadership Transition
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentXeris reported positive top-line data from the Phase 2 dose-finding study of XP-8121 for hypothyroidism, reiterating their anticipated product profile and suggesting improved bioavailability and greater efficacy.
LeadershipThe new incoming CEO John Shannon brings over 40 years of experience in the pharma/healthcare industry, with expertise in sales, US/global marketing, operations/manufacturing, and strategic planning.
Revenue GrowthPreliminary 2Q24 total revenues of $47M were approximately 13% and 5% above analyst and consensus estimates, respectively, driven by growth in Gvoke and Recorlev sales.
Bears Say
Financial PerformanceXeris reported financial results with total net product revenues of ~$40M, approximately 6%/4% below analyst and FactSet consensus estimates.
Operational IssuesGvoke’s underperformance versus Street expectations was related to the cyberbreach at Change Healthcare that impacted the Gvoke business, resulting in a one-time loss of ~$3M in Gvoke revenues.
Product Safety65% of participants reported at least 1 treatment-emergent adverse event, with fatigue being notable in 22% of cases, necessitating further understanding of XP-8121's tolerability profile in the upcoming Ph.3.
---
Ownership Overview
13.37% Insiders
8.28% Mutual Funds
11.06% Other Institutional Investors
67.29% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
XERS FAQ
What was Xeris Pharmaceuticals’s price range in the past 12 months?
Xeris Pharmaceuticals lowest stock price was $1.46 and its highest was $3.26 in the past 12 months.
What is Xeris Pharmaceuticals’s market cap?
Currently, no data Available
When is Xeris Pharmaceuticals’s upcoming earnings report date?
Xeris Pharmaceuticals’s upcoming earnings report date is Aug 07, 2024 which is 93 days ago.
How were Xeris Pharmaceuticals’s earnings last quarter?
Xeris Pharmaceuticals released its earnings results on May 09, 2024. The company reported -$0.14 earnings per share for the quarter, missing the consensus estimate of -$0.106 by -$0.034.
Is Xeris Pharmaceuticals overvalued?
According to Wall Street analysts Xeris Pharmaceuticals’s price is currently Undervalued.
Does Xeris Pharmaceuticals pay dividends?
Xeris Pharmaceuticals does not currently pay dividends.
What is Xeris Pharmaceuticals’s EPS estimate?
Xeris Pharmaceuticals’s EPS estimate is -$0.1.
How many shares outstanding does Xeris Pharmaceuticals have?
Xeris Pharmaceuticals has 148,255,660 shares outstanding.
What happened to Xeris Pharmaceuticals’s price movement after its last earnings report?
Xeris Pharmaceuticals reported an EPS of -$0.14 in its last earnings report, missing expectations of -$0.106. Following the earnings report the stock price went up 1.622%.
Which hedge fund is a major shareholder of Xeris Pharmaceuticals?
Among the largest hedge funds holding Xeris Pharmaceuticals’s share is Fairfax Financial Holdings Ltd. It holds Xeris Pharmaceuticals’s shares valued at 335K.
---
Xeris Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.75 (91.53% Upside)
$4.75 (91.53% Upside)
Blogger Sentiment
Bullish
XERS Sentiment 80%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 127.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $10.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.4%
Last 30 Days ▲ 2.0%
Last 30 Days ▲ 2.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-1.87%
12-Months-Change
Fundamentals
Return on Equity
-617.16%
Trailing 12-Months
Asset Growth
4.75%
Trailing 12-Months
Company Description
Xeris Pharmaceuticals
Xeris Pharmaceuticals, Inc.is a pharmaceutical company, which develops and commercializes ready-to-use, liquid-stable injectables. It offers XeriSol™ and XeriJect™ formulation technologies. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Austin, TX.
---
XERS Earnings Call
Q1 2024
0:00 / 0:00
---
XERS Stock 12 Month Forecast
Average Price Target
$4.75
▲(91.53% Upside)
Technical Analysis
Best Analysts Covering XERS
1 Year
1 Year Success Rate
8/15 ratings generated profit
1 Year Average Return
+5.79%
reiterated a buy rating 5 months ago
Copying Oren Livnat's trades and holding each position for 1 Year would result in 53.33% of your transactions generating a profit, with an average return of +5.79% per trade.
---